Lin Chen

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam et al. · Annals of Oncology · 2015 · 735 citations

Medicine, Oncology, Pharmacology +13

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

Medicine, Oncology, Pharmacology +14

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14

Associations of Intrapancreatic Fat Deposition With Incident Diseases of the Exocrine and Endocrine Pancreas: A UK Biobank Prospective Cohort Study

Xiaowu Dong, Qingtian Zhu, Chenchen Yuan et al. · The American Journal of Gastroenterology · 2024 · 61 citations · Full text

Medicine, Biostatistics, Endocrinology +16

Phase III Study of Apatinib in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

J. Li, Shu-Kui Qin, Jianming Xu et al. · Annals of Oncology · 2014 · 21 citations · Full text

Medicine, Oncology, Pharmacology +8